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During May 2009–April 2010, we analyzed 692 samples 
of pandemic (H1N1) 2009 virus from patients in Mexico. We 
detected the H275Y substitution of the neuraminidase gene 
in a specimen from an infant with pandemic (H1N1) 2009 
who was treated with oseltamivir. This virus was susceptible 
to zanamivir and resistant to adamantanes and oseltamivir.
I
n March and early April 2009, a new strain of inﬂ  uenza 
A virus that contained genes from the Eurasian–North 
American triple reassortant and classical swine lineage vi-
ruses emerged in North America (1,2). By May 21, 2010, a 
total of 214 countries and overseas territories or communi-
ties had reported laboratory-conﬁ  rmed pandemic (H1N1) 
2009, which resulted in at least 18,097 deaths in patients 
with PCR-conﬁ  rmed illness (3). In Mexico 72,533 cases 
(1,228 deaths) were PCR conﬁ  rmed by the second week of 
May 2010 (4).
To control inﬂ  uenza A virus infections, the US Food 
and Drug Administration has approved the use of matrix 
2 (M2) blockers, amantadine and rimantadine, and the 
neuraminidase (NA) inhibitors (NAIs), oseltamivir and 
zanamivir (5). However, for pandemic (H1N1) 2009, ther-
apeutic options are limited to the NAIs because this virus 
has a swine virus–origin M2 gene, which contains a mu-
tation associated with resistance to adamantanes (6). NAI 
resistance in pandemic (H1N1) 2009 viruses has been rare; 
nevertheless, 285 oseltamivir-resistant cases were reported 
worldwide as of April 14, 2010 (7). All oseltamivir-resistant 
viruses have the H275Y substitution that confers resistance 
to oseltamivir but not to zanamivir. Spread of oseltamivir-
resistant seasonal inﬂ  uenza A virus (H1N1) was ﬁ  rst de-
tected in 2007, and this virus has now become the predomi-
nant lineage of inﬂ  uenza A virus (H1N1) in humans (8,9). 
This ﬁ  nding raises strong concerns that the H275Y muta-
tion could become dominant in pandemic (H1N1) 2009 as 
well. We report oseltamivir-resistant pandemic (H1N1) 
2009 detected through virologic surveillance in Mexico.
The Study
We aimed to determine the drug susceptibility of pan-
demic (H1N1) 2009 in Mexico. We randomly selected 692 
independent clinical samples (452 cell culture supernatants 
and 199 nasopharyngeal swab specimens [NPS]) or viral 
isolates, mostly from patients hospitalized in Mexico and 
from a few symptomatic patients with highly suspected 
oseltamivir- resistant infections (31 NPS and 10 lung bi-
opsy specimens from patients who died). The study was 
conducted during July 2009–May 2010. All samples were 
received during May 2009–April 2010 at the Institute of 
Epidemiologic Diagnosis and Reference (InDRE [Mexico 
City, Mexico]); all were positive for pandemic (H1N1) 
2009 by real-time reverse transcription–PCR (RT-PCR), 
according to the procedure recommended by the Centers 
for Disease Control and Prevention (Atlanta, GA, USA) 
and the World Health Organization.
Samples were collected from patients in all Mexican 
states. Patients did not differ signiﬁ  cantly by sex, and per-
sons 10–29 years of age were most commonly affected, 
similar to the number of incident cases of acute respiratory 
infection in Mexico (Table 1). Viral RNA was extracted by 
using either MagNA Pure LC Total Nucleic Acid Isolation 
Kit (Roche Diagnostics, Rotkreuz, Switzerland) or QIAmp 
Viral RNA Mini Kit (QIAGEN, Hilden, Germany).
An endpoint RT-PCR was performed for all 692 sam-
ples screened for the H275Y molecular marker by using 
the Superscript III RT-PCR system (Invitrogen, Carlsbad, 
CA, USA) and FLUAN1–721F and FLUAN1–924R prim-
ers spanning position 275 of the NA gene (Table 2). Direct 
sequencing of these PCR products was performed by us-
ing a sequencing primer (FLUAN1–904R, Table 2) and the 
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All the sequences obtained indicated that the H→Y 
mutation at the NA 275 residue was absent, except in 1 NPS 
from an 8-month-old girl (A/Mexico/InDRE797/2010). This 
patient received oseltamivir treatment from the evening of 
January 22 through January 27. She had no known history 
of travel, contact with a person treated with this drug, or di-
agnosed immunodeﬁ  ciency. Her clinical record mentioned 
2 respiratory events in the 2 months before the inﬂ  uenza 
diagnosis: broncholitis, which required hospitalization, and 
readmission to the hospital 2 weeks after discharge because 
of inﬂ  uenza-like illness and severe pneumonia. In addition 
to oseltamivir, the child required other antimicrobial drugs 
(ceftriaxone and vancomycin) and mechanical ventilation. 
She slowly recovered.
The clinical specimen was collected, and pandemic 
(H1N1) 2009 was laboratory conﬁ  rmed on January 27, 
2010. In this sample and in isolating the virus we further 
analyzed, we discarded any of the 9 previously described 
mutations (5,10) associated with resistance to NAIs (V116, 
I117, E119, Q136, K150, D151, D198, I223, and N295 [N2 
numbering]) by the full sequence of the NA gene by using 
2 overlapping RT-PCR products (Figure 1, Table 2). The 
complete NA sequence of the A/Mexico/InDRE797/2009 
virus obtained from NPS and MDCK isolate (GenBank ac-
cession no. CY057074) conﬁ  rmed the H275Y substitution 
and showed no other NA mutations known to be associ-
ated with NAI resistance (Figure 2, panel A). Pyrosequenc-
ing analysis performed on the clinical specimen from the 
8-month-old patient showed oseltamivir-resistant H275Y 
and wild-type H275 virus variants (Figure 2, panel B). The 
A/Mexico/InDRE797/2009 virus was tested at the Centers 
for Disease Control and Prevention by using an NA inhibi-
tion assay (NA-Star kit, Applied BioSystems) and showed 
an ≈120-fold increase in oseltamivir 50% inhibitory con-
centration over that of a sensitive control (27.3 nmol/L vs. 
0.23 nmol/L; this result was consistent with H275Y and 
H275 variants. No change in zanamivir susceptibility was 
detected (0.32 nmol/L vs. 0.30 nmol/L), which was in ac-
cord with the NA sequencing analysis. We also sequenced 
the M2 gene and conﬁ  rmed the S31N substitution that con-
fers M2 blocker resistance. Sequencing of the HA gene 
showed that the substitution D222G, potentially associated 
with severe clinical outcome (12), was not present in this 
isolate (data not shown).
In addition, 24 virus isolates collected during Decem-
ber 2009–January 2010 were tested in the NA inhibition 
assay. All were sensitive to both NAIs, with 50% inhibitory 
concentrations of 0.12–0.29 nmol/L and 0.17–0.36 nmol/L 
for oseltamivir and zanamivir, respectively.
No other molecular markers of NAI resistance, such 
as at residues Q136, K150, or D151, which might confer 
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Table 1. Characteristics of patients with pandemic (H1N1) 2009 
reported to the Institute of Epidemiologic Diagnosis and 
Reference, by age group, Mexico, May 2009–April 2010 
Age group, y 
No. (%) patients 
Female Male Total 
0–1 9 6 15
1–4 30 23 53
5–9 40 34 74
10–19 67 83 150
20–29 66 65 131
30–39 25 34 59
40–49 25 24 49
50–59 19 19 38
>60 5 6 11
Unknown 51 61 112
Total 337 (48.6)  355 (51.3)  692
Table 2. Primer sets used in reverse transcription–PCR and Sanger sequencing of isolates for pandemic (H1N1) 2009, Mexico, May 
2009–April 2010* 
Primer Sequence,  5ƍ o 3ƍ Target/position,  nt 
FLUAN1–721F GTAATGACCGATGGACCAAG  NA/721 
FLUAN1–924R CTGGTTGAAAGACACCCAC  NA/924 
FLUAN1–904R GTCGATTCGAGCCATGCCAG  NA/904 
MBTuni-12† ACGCGTGATCAGCAAAAGCAGG  NA/5ƍ UTR 
MBTuni-13† ACGCGTGATCAGTAGAAACAAGG  NA/3ƍ UTR 
*NA, neuraminidase; UTR, untranslated region. 
†Primer sets previously published in 2009 (11). 
Figure 1. Reverse transcription–PCR (RT-PCR)/sequencing 
primers scheme for the neuraminidase (NA) gene. A) Primer 
position for screening RT-PCR protocol. B) Primer position and the 
2 overlapping RT-PCR products for the complete NA sequence. 
UTR, untranslated region.Oseltamivir-Resistant Pandemic (H1N1) 2009
zanamivir resistance, were observed in the isolate from the 
8-month-old girl. The functional NI assay conﬁ  rmed the 
oseltamivir resistance and susceptibility to zanamivir of 
the virus. Both variants (H275Y and wild type) were pres-
ent in the clinical specimen and its matching virus isolate, 
which is not unusual (13). The proportion of resistant virus 
(1 [0.14%] of 692 analyzed cases) is lower than has been 
described, perhaps because of the limited analysis. Analy-
sis of additional samples will enable detection of additional 
cases. The M2 S31N substitution, the adamantane resis-
tance marker, also was present, as is expected in this virus.
Conclusions
Concern exists that an oseltamivir-resistant variant of 
pandemic (H1N1) 2009 virus may emerge and spread in 
a manner similar to that of oseltamivir-resistant seasonal 
inﬂ  uenza A virus (H1N1) (14). Because pandemic (H1N1) 
2009 virus is already resistant to adamantanes, oseltami-
vir resistance would leave zanamivir as the only antiviral 
treatment option. Consequently, close monitoring of the 
antiviral susceptibility of pandemic (H1N1) 2009 strains is 
critical for controlling the spread of this virus (15).
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